1. Lupin Press Meet, October 7, 2003 Lupin Press Meet October 7, 2003

2. Lupin Press Meet, October 7, 2003 Background and Origin Current Operations and Strengths Recent Business Successes The Building Blocks Glimpse into the Future Strategy for the Future

3. Lupin Press Meet, October 7, 2003 Background and Origin

4. Lupin Press Meet, October 7, 2003 Background and Origin Started in 1968 by the Founder Chairman Dr Desh Bandhu Gupta in Mumbai Now spread over 6 locations in India and a location in Thailand Represented through Sales offices in UK, USA, Hong Kong, Japan and CIS Widely held and listed on all major Stock Exchanges 3300 employees

5. Lupin Press Meet, October 7, 2003 Current Operations and Strengths

6. Lupin Press Meet, October 7, 2003 Current Operations Among the top 6 Pharma companies in India Turnover of Rs 1120 Cr and PBT of Rs 97 Cr Integrated player with significant presence in both API and Formulations API Sales spread over more than 50 countries globally Strong Formulation Sales across India 1/3 rd of Revenues from Exports

7. Lupin Press Meet, October 7, 2003 Performance at a glance Rs’ crore SalesPBT 2000-01903650 2001-02957964 2002-031120971 CAGR 11%CAGR 22%

8. Lupin Press Meet, October 7, 2003 Segment Trends  Formulations in India grew at 19 % in Q1 ( FY 03-04) outperforming the market growth of 6 % as per ORG. This segment will continue to be a growth driver.  Exports surged by 41 % and is expected to be the leading growth driver in the future.  Regulated markets contribution to the company topline stands at 31 % and is likely to grow further.

9. Lupin Press Meet, October 7, 2003 Strengths Increasing Presence in the Advanced markets of US and Europe 9 out of 10 Plants are US FDA approved Strong Integrated R&D program encompassing NCE, NDDS and Process Research World Leader in Anti TB Strong Position in Cephalosporins and Cardiovasculars

10. Lupin Press Meet, October 7, 2003 Recent Business Successes

11. Lupin Press Meet, October 7, 2003 Recent Business Successes Consolidation of our Presence in Advanced Nations 5 ANDAs filed and 3 approved 12 DMFs filed First Generic formulation (Cefuroxime Axetil) launched in US 110 patents filed and 50 granted Ceff-ER, world’s first once a day Cephalexin developed and launched 8 Brands in India’s top 300

12. Lupin Press Meet, October 7, 2003 Strategy for the Future

13. Lupin Press Meet, October 7, 2003 Strategy for the Future Advanced Generic Mkts Expand APIs by partnering with niche players Grow formulations through Alliances Direct marketing of Branded formulations API and Intermediates - In Domestic and Developing markets by emphasizing on Cost leadership and long term supply contracts Formulations – In Domestic and Select Developing markets through consolidating the Acute therapy segments and building Chronic lifestyle segments

14. Lupin Press Meet, October 7, 2003 The Building Blocks

15. Lupin Press Meet, October 7, 2003 Building Blocks Professionalization of Mgmt by inducting top notch senior professionals State of art IT initiative in place Strong QA program in place Focus on expanding capacity Leveraging R&D strengths for Business Comprehensive Process for Intellectual Property Management Two World class Investors being inducted Financial Restructuring Slew of HR initiatives Linkages with Strategy and Operations Enhancing the Leadership pool Very high degree of focus on Corporate Governance

16. Lupin Press Meet, October 7, 2003 Glimpse into the Future

17. Lupin Press Meet, October 7, 2003 Lupin of the Future Be among top 3 pharma companies in India Majority of Revenues from the Advanced markets To have Higher and Sustainable earnings R&D program to contribute significantly to the Bottomline Moving the Business Model up the Value Chain by enhancing the Product and Geography Mix To be known as a Venerable Institution rather than a mere Organization Maximizing Value for all Stakeholders